Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 158

Results For "Research"

2024 News Found

Valneva receives funding for Covid-19 vaccine from Scotland
Biotech | February 21, 2022

Valneva receives funding for Covid-19 vaccine from Scotland

The grants are expected to be received over the next three years, commencing March 2022


USFDA lifts clinical hold on submission of Covaxin
News | February 20, 2022

USFDA lifts clinical hold on submission of Covaxin

Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades


Moderna expands Its mRNA pipeline with new development programs
Biotech | February 20, 2022

Moderna expands Its mRNA pipeline with new development programs

These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.


Aizon’s CEO John Vitalie named one of the top 25 Biotech CEOs of 2022
News | February 19, 2022

Aizon’s CEO John Vitalie named one of the top 25 Biotech CEOs of 2022

The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector


cbdMD becomes first American CBD brand to receive UK validation
Biotech | February 19, 2022

cbdMD becomes first American CBD brand to receive UK validation

The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK


Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).


Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
News | February 19, 2022

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study


Indian pharma industry needs a winning partnership
News | February 19, 2022

Indian pharma industry needs a winning partnership

The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines


Covid-19 fuels innovative PCR-based detection methods
Medical Device | February 19, 2022

Covid-19 fuels innovative PCR-based detection methods

According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years


USFDA accepts Mirati Therapeutics' New Drug Application for Adagrasib
Drug Approval | February 18, 2022

USFDA accepts Mirati Therapeutics' New Drug Application for Adagrasib

The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022